載入中
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
前收盤價
US$13.07
+US$0.47 · +3.73%
盤中時間採用ET。市場資料可能有所延遲。
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
日內區間
目前US$13.07
52週區間
目前US$13.07
盤中時間採用ET。市場資料可能有所延遲。
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
日內區間
目前US$13.07
52週區間
目前US$13.07
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 6767.1萬 USD | 5787.7萬 USD | 3627.5萬 USD | 5212.1萬 USD | 3305.3萬 USD |
| 銷貨成本 | 1592.3萬 USD | 1028.5萬 USD | 897.6萬 USD | 757.2萬 USD | 689.1萬 USD |
| 毛利 | 5174.8萬 USD | 4759.2萬 USD | 2729.9萬 USD | 4454.9萬 USD | 2616.2萬 USD |
| 研究與開發 | 3.89億 USD | 4.66億 USD | 4.35億 USD | 4.2億 USD | 2.3億 USD |
| 銷售、一般及管理費用 | 1.2億 USD | 1.26億 USD | 1.16億 USD | 9030.6萬 USD | 7109.6萬 USD |
| 營業費用 | 4.93億 USD | 5.82億 USD | 5.43億 USD | 5.03億 USD | 2.94億 USD |
| 利息收入 | 2919.5萬 USD | 4780.7萬 USD | 4983.2萬 USD | 854.2萬 USD | 128.3萬 USD |
| 折舊和攤銷 | 1592.3萬 USD | 1028.5萬 USD | 897.6萬 USD | 757.2萬 USD | 689.1萬 USD |
| 營業利益 | −4.41億 USD | −5.34億 USD | −5.15億 USD | −4.58億 USD | −2.68億 USD |
| 淨利 | −4.13億 USD | −5.19億 USD | −4.81億 USD | −4.74億 USD | −2.68億 USD |
公司資料更新於 2026年10月11日。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
ARK Innovation ETFARKK1.42億2.06%55.62億 USD0.75%US$89.62+2.31%
State Street SPDR S&P Biotech ETFXBI5473.79萬0.55%98.74億 USD0.35%US$153.77+3.00%
Vanguard Morningstar Total Stock Market ETFVTI5473.77萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM4566.77萬0.06%787.4億 USD0.19%US$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB3969.03萬0.02%1853億 USD0.03%US$289.48+0.64%
ARK Genomic Revolution ETFARKG3782.56萬1.85%15.57億 USD0.75%US$51.30+4.08%
Vanguard Morningstar Small-Cap Growth ETFVBK2273.43萬0.05%447億 USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF2064.44萬0.02%954億 USD0.05%US$235+0.80%ARK Innovation ETFARKKState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBARK Genomic Revolution ETFARKGVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
